ESM Technologies and joint-venture partner Stratum Nutrition are pleased to announce a new, pre-clinical study reporting the beneficial effects of triple-action NEM® brand eggshell membrane on multiple indices of inflammation and arthritis in collagen-induced arthritic rats, the gold-standard animal model of human rheumatoid arthritis (RA). The study was published in Modern Rheumatology (DOI: 10.1080/14397595.2016.1259729), and supports and extends previous research showing the benefit of NEM® for pain and stiffness in humans with osteoarthritis and in a rodent model of osteoarthritis.

This study was conducted at Bolder BioPATH, Inc. (Boulder, CO) in rats with developing collagen-induced arthritis. Rats received once daily either NEM® (52 mg/kg body weight corresponding to the human equivalent dose of 500 mg/day), methotrexate, or vehicle control. Treatment with NEM® resulted in a significant reduction in ankle swelling within two days after measurable swelling began. Histopathologically, NEM-treated rats had significantly less inflammation, cartilage damage, bone resorption, and pannus formation in both their ankle and knee joints compared to vehicle control animals. Serum CTX-II (collagen type II C-telopeptide) and COMP (cartilage oligomeric matrix protein) were reduced by 32% and 40%, respectively, on Day 13 in NEM-treated rats. Synovial Interleukin (IL)-1β, a key mediator of inflammation, was reduced by 50% in NEM-treated rats when evaluated by knee lavage.

Co-author Dr. Alison Bendele, a pioneer in developing and validating animal models of inflammation and arthritis, comments on the study: “Using the gold standard animal model of RA, a strong study design that included all required controls along with a comparator drug (methotrexate), and the use of validated, complementary indices of efficacy including physical, histological, and biochemical assessments, we found that supplementation with NEM® significantly improved every index to meaningful degrees. These results provide impressive new evidence for the immune modulating activity of NEM® in the context of collagen-induced inflammation and arthritis, along with a solid rationale for continuing this line of research.” This study, along with additional published studies, provides further substantiation for NEM® supporting a healthy inflammatory response.

For more information on this study or other previously published studies, please contact Dr. Kevin Ruff at: kruff@esmingredients.com.

Rimouski (Quebec), February 27, 2017 – innoVactiv, a Canadian company dedicated to the development of science-based specialty ingredients, today announces the commercial launch of MYOCERAM™, a new line of clinically-tested beauty-from-within ingredients containing high-purity and high potency plant ceramides. The MYOCERAM™ product line will be showcased at the upcoming Engredea / Natural Product Expo West tradeshow on March 10 in  Anaheim, California.

MYOCERAM™ is the result of many years of extensive research and development by Nippon Flour Mills Co. Ltd. (NIPPN), a 120-year-old public Japanese company engaged in a wide range of food businesses including flour milling, food ingredients, processed and frozen foods, health foods as well as pet foods. Building on its tradition of excellence in grain milling, NIPPN scientists had been focusing their long-time research on plant-based ceramides which ultimately yielded high-purity ceramides derived from rice and corn. Following these discoveries, NIPPN established multiple research partnerships to demonstrate their efficacy in improving skin condition which has lead to the commercialization of these innovative plant-based ceramides under the tradename MYOCERAM™.

Although beauty-from-within supplements are a staple in Asia, this market is still set to boom in North America. “Skin is our body’s largest organ. Yet how nutrition affects our skin is a research field that has been overlooked for many years. When taken orally at a convenient low dosage, MYOCERAM™ boosts the expression of enzymes responsible for endogenous ceramide production within the skin itself. These new ceramides can then incorporate lamellar bodies between each cell to strengthen the outermost corneous skin layer, just as they would through our normal skin physiology”, explains Jocelyn Bérubé, Executive & Scientific Director, Health & Nutrition of innoVactiv.

“We are pleased to enter into this partnership with innoVactiv, allowing us to extend the commercial coverage of MYOCERAM™ to North America. Since its development, MYOCERAM™ has been incorporated into dozens of supplements and foods in Japan and has been saluted for its high purity and lower daily dosage compared to other available plant ceramides”, said Mr. Ko Murai, Associate Director and General Manager of Health Care Business Division at NIPPN.

We are proud to partner with NIPPN, a strong and reputable company. Their focus on quality and service is perfectly lined-up with our own corporate values. Furthermore, cosmetics and dietary ingredients are the two main pillars on which innoVactiv was founded, and the integration of MYOCERAM™ into our portfolio is thus a natural extension of our core strengths in these two areas”, said Patrice Dionne, CEO of innoVactiv.

Manufacturers interested in learning more about MYOCERAM™ are invited to visit innoVactiv’s booth (#765) at the upcoming Engredea tradeshow or contact us at info@innovactiv.com.

East Windsor, NJ (January 10, 2017) –Sabinsa’s multi-enzyme complex DigeZyme®, a proprietary blend of non-animal sourced enzymes, was shown to have the potential for more rapid recovery from Delayed Onset Muscle Soreness (DOMS) in a study published in Sports Nutrition and Therapy: Multi−Enzyme Complex for the Management of Delayed Onset Muscle Soreness after Eccentric Exercise: A Randomized, Double Blind, Placebo Controlled Study

Delayed onset muscle soreness (DOMS) is one of the outcomes of inflammation due to microscopic wear and tear in the muscles caused by strenuous exercise. While some muscle soreness is typical of any exercise regimen and usually peaks around 36-48 hours after the exercise event, in athletes or even regular gym-goers unaccustomed or high intensity exercise may lead to sustained inflammatory response, causing prolongation of skeletal muscle recovery. DOMS may lead to passive stiffness, swelling and pain in muscles, which may affect performance as well as recovery.

In this prospective, double blind, randomized, placebo controlled trial on 20 healthy male subjects, the analgesic effect of DigeZyme in management of DOMS were compared to placebo. While DigeZyme’s role in supporting improved digestive health is well recognized, this is the first attempt to evaluate its role in DOMS resulting from muscle overload or strenuous exercise.

Supplementation with 50 mg of DigeZyme three times a day demonstrated significant improvement in both subjective pain and muscle tenderness after eccentric exercise. This study establishes the role of DigeZyme in sports nutrition, especially as a post exercise recovery supplement.

DigeZyme is available as a powdered blend which can be mixed with other sports nutrition ingredients as well commercialized as a standalone product. “This new study, gives a new twist to a classic product of ours, DigeZyme,” said Sabinsa Marketing Director Shaheen Majeed.

“Well known for use in digestive health, we have now studied DigeZyme for this specific sports indication. Enzymes have been part of the sports supplements category, and DigeZyme has enjoyed its place in many sports products, mainly to have enzymes breakdown proteins and carbohydrates. Sabinsa has now given an additional clinical indication that no other enzyme blend has done before – DOMS. Our blend for this indication is now patent pending.”

Gnosis has just launched a new YouTube channel (Gnosis-bio) to share knowledge and scientific backing about its ingredients, unlock not very well-known and often critical aspects of its ingredients and provide new highlights and advancements in the several fields of application of health and wellbeing.

The new Gnosis marketing tool would like to represent a way for the visitor to open a short-lived window of time where being flashed by pictures and brief concepts to eventually deepen later through scientific lecture or visiting our web-sites. Videos of speeches led by scientists, lectures and conferences held in the most important nutritional events in the world,  let Gnosis’ YouTube visitors to discover, in quick and informal way, how a right nutrition may contribute to human health, giving them counsels and recommendations to manage their wellbeing better than ever before.

In the recent years nutraceutical industry has evolved greatly in term of market increase, quality requirements and awareness of consumers with the dietary supplement use and the consumer confidence that are on the rise globally.

According to the most recent annual survey conducted by Ipsos Public Affairs on behalf of the Council for Responsible Nutrition (CRN), published in October 2016, seventy-one percent of U.S. adults—more than 170 million—take dietary supplements  with an increase in usage among adults between the ages 18–34 and with the oldest population surveyed (adults aged 55+) that maintains the highest percentage of supplement use at 74 percent. Moreover, 85 percent of U.S. adults have overall confidence in the safety, quality and effectiveness of dietary supplements. Among supplement users it’s even higher, with 96 percent indicating confidence.

All at once, the consumers take a more active role in managing their health and show a real hunger for knowledge of health benefits and scientific substantiation of finished products and/or active ingredients. They can be defined as proactive healthcare consumers, with a remarkable aptitude to interact in social media channels, and the tendency to share their experiences and opinions. Social networks play an important role in consumers decision making, effectively facilitate their education and create a direct connection for responsible consumption toward greater transparency from ingredients producers.

Gnosis-bio YouTube channel starts with Quatrefolic® and Mythocondro® short videos, two products developed to overcome and change two consolidated and mature markets – such as folate and chondroitin sulfate – with the only target to optimize benefits and reduce safety concerns and less bioavailability.

The Quatrefolic® video: Watch the video here

The Mythocondro® video: Watch the video here

On the occasion of the World Osteoporosis Day which takes place every year on October 20^th, Gnosis has participated at the special event “Supplements in the non-pharmacologic treatment of osteoporosis” with a speech held by Dr. Luca Tiano – presenting new highlights and evidence of the use of vitamin K2  menaquinone-7 in the form of vitaMK7® and K2&Olive™. Researcher in Biochemistry, Dr Luca Tiano actually works in the Department of Odontostomatologic and Specialized Clinical Sciences at the Polytechnic University of Marche (Ancona –Italy).

This vitamin has attracted  most of the attention of the audience, made up of medical doctors and scientists,  flocked at the conference to be updated on new and effective nutrients in bone health.

Dr. Tiano has described the role of  vitamin K2  the in the form of menaquinone-7 in bone metabolism, according to what the scientific research has elucidated in the last years, showing as it may help in reducing the risk of osteoporotic fractures and could be considered a good nutrient for the prevention of osteoporosis.

In particular he highlighted the benefits of vitaMK7®, the natural Vitamin K2  obtained through a patented biofermentation process of Bacillus subtilis spp natto

The importance of the consumption of folate to support the body’s well-being is now widely recognized and folate definitely represents one of the most common nutritional ingredients used during all stages of life.

Very recently ConsumerLab has published a new report titled “B Vitamin Supplements and Energy Drinks (Including B Complexes, Niacin, B-6, B-12, Biotin, Thiamin, and Folate)” where several finished dietary supplements, commercialized in the US market and containing the (6S)-5-methyltetrahydrofolate (5-MTHF) – the biological active form of folate – or folic acid, have been tested.

With a long history of certifying supplement, ConsumerLab is the leading provider of independent test results and information to help consumers and healthcare professionals to identify the best quality health and nutrition products.

The report mentions the rational use of reduced folate and describes why they are suggested for people with a gene polymorphism of the enzyme MTHFR (methyltetrahydrofolate reductase) that drives to an impairment in the metabolization of folic acid and folate from food or supplements to (6S)-5MTHF also named L-methylfolate, the active form of folate in the body. According to the data shared by the report, roughly 33% of Americans carry one copy of a common MTHFR gene mutation (C677T). People with two C677T mutations is about 11% of Americans.

Aberrant folate metabolism has adverse effects on human health, including increased risk for birth defects, cancer, cardiovascular disease , end-stage renal disease, diabetic neuropathy, and CNS disorders such as depression and cognitive impairment (Tsang BL et al. Am. J. Clin. Nutr. 2015).

Supplements with (6S)-5MTHF, alone or in combination, have been positively tested among the other. They have been promoted by the manufacturer for use by people with this common genetic defect.

ABOUT QUATREFOLIC® Among reduced folate, Quatrefolic®, the Gnosis’ proprietary innovActive folate made up of the glucosamine salt of (6S)-5-MTHF, is even more recognized as the folate of reference in the US market, as a direct source of the 5-MTHF that doesn’t need to be metabolized and can enter immediately folate-dependent pathways. It has established itself as the benchmark for the whole industry of folate derivatives. The independent prove of the stability of Quatrefolic® in supplements, together with the already known advantages of this recommended reduced folate demonstrate again like it is a winning mix of efficacy, innovation and safety.

For more information contact marketing@gnosis-bio.com

Enthusiastic feed-back of nutraceutical industry at VENDORBRIEF presentation of Mythocondro® held last week during Supply Side West, in Las Vegas.

Prof. Nicola Volpi, Associate Professor of Biochemistry at the University of Modena and Reggio Emilia, Italy, one of the worldwide expert in the field of chondroitin sulfate (CS), gave a successful speech on the concerns of current industrial production of animal-derived chondroitin sulfate and introduced Mythocondro®, the pioneering ingredient developed by the Italian based company Gnosis, through an innovative fermentation technology.

Mythocondro® promises to resolve the long-standing acknowledged problem of poor quality and potential safety issues of animal-derived CS.

The speech was also the occasion to issue and present a book that describe and unlock the insights about this new Non-Animal Chondroitin Sulfate, with relevant effectiveness in joint disease.

Going inside the speech, Prof. Volpi offered a trip into chondroitin world with an extensive overview of the aetiopathogenesis of OA, of the current database of CS in the treatment of OA, the relative safety concerns of animal-derived sources and the relevant description and clinical evidence of Mythocondro®.

CS is a natural sulfated GAG which play a significant role in biological processes as it is abundantly distributed in humans, other mammals and invertebrates. Based on its structural diversity in chain length and sulfation patterns, CS provides specific biological functions in cell adhesion, morphogenesis, neural network formation and cell division.

Even if the clinical benefits of CS have been established by a large number of human trials it is also known that animal-derived chondroitin is now acknowledged within the nutraceuticals industry as one of the most adulterated supplements in the market. This poses serious concerns about the quality and the safety of the ingredient.

Animal CS safety concerns*
Animal CS supplied to the market is extracted from cartilaginous feedstocks using organic solvents, with purification processes that may cause chemical degradation/desulfation and loss of activity along with an uncontrolled and unreliable supply chain of CS raw materials].

Source material, manufacturing processes, the presence of contaminants and many other factors contribute to the quality, structure and physico-chemical properties of the final product and of the overall biological and pharmacological activities of this bioactive (macro)molecule

[1,2].

The quality profile of animal-derived CS changes with the tissue, organ and species[3]. Furthermore, as well known, the biological and pharmacological properties may vary with the structure and the oral absorption may be influenced by the different physicochemical properties[4,5]. Finally, due to the extractive origin of CS, the presence of virus or prions cannot be excluded[6], as well as other various natural bioactive (macro)molecules present as contaminants in CS extracts in different amount[7,8], or voluntary adulteration by similar artificial compounds[9], or a restriction use related to religious issues.

Mythocondro® in the book
In the Volpi’s book a novel chondroitin sulfate of non-animal origin is presented pointing out why Mythocondro®, resolves the long-standing acknowledged problem of poor quality and potential safety issues of animal-derived CS.

Mythocondro® based on fermentation technology, is characterized by high purity, homogeneous structure and physico-chemical properties, highly, point-by-point controlled production process for a highly controlled and reproducible final product, no toxicity in acute and chronic animal models, improved biological activities, anti-inflammatory and protective properties in an osteoarthritis animal model study.
It represents a reliable solution to the growing demand of effective prevention of the bone health in aging population and is the first CS suitable for vegetarians and free from restrictions of use related to religious and supply issues.

About the author
Nicola Volpi is Associate Professor of Biochemistry at the University of Modena and Reggio Emilia, Italy and he is one of the worldwide expert in the field of chondroitin sulfate.
Author of many publications, invited as speaker to several national and international congresses, Prof. Volpi is also Editor of three published international books with great impact on the international scientific community.

He is an authority on the application of the analytical methodologies essential for the understanding of the structure, properties and quality of chondroitin sulfate and derivatives and collaborates both with Italian and International research groups as well as with Companies to develop (macro)molecules with improved biological and potential pharmacological properties.
Prof. Volpi has been member of the USP (U.S. Pharmacopoeia) Commission in 2000 for “Analytical determination of Chondroitin sulfate sodium”.

The book will be available upon request, at marketing@gnosis-bio.com

*References:

1. N (Ed). 2006. Chondroitin sulfate: structure, role and pharmacological activity. Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo: Academic Press.
2. Martel-Pelletier J, Farran A, Montell E et al. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules 2015;20:4277-89.
3. Martel-Pelletier J, Boileau C, Pelletier JP et al. Cartilage in normal and osteoarthritis conditions. Clin Rheumatol 2008;22:351-84.
4. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Ost Cartil 2002;10:768-77.
5. Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Ost Cartil 2003;11:433-41.
6. Schonberger LB. New variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Infect Dis Clin North Am 1998;12:111-21.
7. Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol 2009;61:1271-80.
8. Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci 2007;96:3168-80.
9. Weiguo Z, Giancaspro G, Adams KM et al. Electrophoretic separation of alginic sodium diester and sodium hexametaphosphate in chondroitin sulfate that interfere with the cetylpyridinium chloride titration assay. J AOAC Int 2014;97: 1503-13.

We are pleased to announce our presence at the Infant Nutrition 2016 online event which will take place on October 18, 2016.

As a valued partner, we invite you to join us online.

Attendance is FREE and you’ll be able to:

• Download our latest product information about Infant Formula Iron Fortification with Lipofer® and view the new corporate blackboard animated video
• Connect and interact with our team
• Discuss any upcoming projects we might be able to help you with

If you are not registered yet, click here to access the official event registration page for your convenience.

We look forward to you joining us online on October 18.